Latest Trading Halts News

333D Limited (ASX:T3D) has told the ASX it is unaware of any undisclosed information that could explain a sharp rise in its share price and trading volume. The company offered no alternative explanation for the move, which took its shares from $0.035 to an intraday high of $0.064.

TerraCom’s securities will remain suspended from ASX quotation after the company failed to lodge its annual report for the year ended 30 June 2026. Reinstatement now depends on the report being filed and ASX considering it appropriate to resume trading.

FirstWave Cloud Technology has sharply reduced its FY26 loss and generated positive operating cash flow as network monitoring and Latin American revenue accelerated. But a $5.35 million net current asset deficiency, covenant breach and planned capital raise leave the turnaround dependent on continued execution.

Suncorp Group has rejected speculation that it is in takeover discussions with Tokio Marine after its shares climbed from $19.05 to $20.18 and trading volumes increased. The insurer told the ASX it had received no takeover offer and knew of no undisclosed information explaining the move.

TerraCom has been suspended from trading while it completes audited FY2026 results expected to include material impairments to its South African and Australian assets. The company has not yet disclosed the size or effect of those write-downs.

Metrics Income Opportunities Trust has been suspended from trading after its responsible entity warned that the audited FY2026 financial report may differ materially from figures released in August. The final report is expected on 30 September, but the filing does not disclose the size or direction of the changes.

Metrics Real Estate Multi-Strategy Fund units have been suspended at the fund’s request after its responsible entity warned that the final audited 2026 financial report may differ materially from figures released in August. The report is expected on 30 September.

Metrics Master Income Trust has been suspended from trading after warning that its audited FY2026 financial report may differ materially from unaudited figures released last month. The final report is expected on 30 September, but the trust has not disclosed the nature or size of the revisions.

Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.

Betashares’ six audited ETFs delivered sharply mixed results for the year ended 30 June 2026, with Bitcoin, Ethereum and gaming funds reporting losses while uranium assets expanded. Post-year-end NAV swings added another layer of volatility, including a 49.67% rise for the Ethereum ETF.

Betashares’ 2026 annual report shows a sharp split across its thematic ETF range, led by a $1.886 billion accounting profit for the Nasdaq 100 ETF and a $97.7 million loss for its Australian technology fund. The report also flags a 24.89% post-year-end fall in the Space Industry ETF’s NAV and a name change for the energy-transition strategy.

Paradigm Biopharmaceuticals has secured a voluntary suspension of its ASX securities while it prepares to release interim analysis results from its PARA_OA_012 Phase 3 trial. The announcement gives no indication whether the clinical readout is favourable or unfavourable, with trading potentially resuming on 28 September subject to ASX approval.